TESTOSTERONE ENANTHATE


Trade Names	DELATESTRYL TESTOSTERONE ENANTHATE XYOSTED (AUTOINJECTOR)
Synonyms	Androtardyl Delatestryl NSC-17591 Primoteston depot Testosterone enantate Testosterone enanthate Testosterone enanthate ciii Testosterone heptanoate Testosteroni enantas Xyosted Xyosted (autoinjector)
Status
Molecule Category	Free-form
UNII	7Z6522T8N9
Parent Compound:	TESTOSTERONE


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	VOCBWIIFXDYGNZ-IXKNJLPQSA-N
Smiles	CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
InChI	InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C26H40O3
Molecular Weight	400.6
AlogP	6.4
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	6.0
Polar Surface Area	43.37
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	29.0

Bioactivity

Mechanism of Action	Action	Reference
Androgen Receptor agonist	AGONIST	Wikipedia FDA


Protein: Androgen Receptor Description: Androgen receptor Organism : Homo sapiens P10275 ENSG00000169083

Cross References

Resources	Reference
ChEBI	9464
ChEMBL	CHEMBL1200335
DrugBank	DB13944
DrugCentral	4609
FDA SRS	7Z6522T8N9
Human Metabolome Database	HMDB0005814
KEGG	C08157
PubChem	9416
SureChEMBL	SCHEMBL42687
ZINC	ZINC000003876080

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).